Substantial advances in clinical programs Update on novel differentiated preclinical programs, including cell therapy Corporate transaction resulting in $80M cash infusion and ~$70M in projected savings Earnings Conference call at 11am ET today LEXINGTON, Mass.

LEXINGTON, Mass., April 27, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its first quarter 2017 financial results before the market opens on Thursday, May 4, 2017.

First patient dosed; combination trials with anti-PD-1 plus anti-CTLA-4 antibodies planned by year-end LEXINGTON, Mass., April 20, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced

Two posters presented at AACR show evidence of ASV™ synergizing with checkpoint blockade LEXINGTON, Mass., April 5, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a clinical stage pipeline of immune checkpoint antibodies and cancer vaccines, today announced that

- Will Host Conference Call at 9am ET Today - LEXINGTON, Mass., March 30, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a clinical stage pipeline of immune checkpoint antibodies and cancer vaccines, today announced that it is reorganizing its business and

LEXINGTON, Mass., March 24, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced participation at the following conferences: The 7 th  Annual William Blair and Maidstone Life Sciences

- Will Host Update Conference Call at 11am ET Today - LEXINGTON, Mass. , March 9, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for

LEXINGTON, Mass., March 7, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that four abstracts on its checkpoint antibodies and cancer vaccine candidates were accepted for poster

LEXINGTON, Mass., March 2, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter and year end 2016 financial results before the market opens on Thursday, March 9, 2017.

Incyte secures global clinical development and commercialization responsibilities for GITR and OX40 programs, converting both from profit-sharing to royalty-bearing arrangements. Agenus to receive $80 million from Incyte: $60 million equity investment at $6 per share and $20 million in accelerated

- Appointment signals clinical focus - LEXINGTON, Mass., Jan. 30, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Jean-Marie Cuillerot, M.D.

LEXINGTON, Mass., Jan. 17, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a clinical trial collaboration with the National Cancer Institute (NCI).

- Third antibody from Agenus to enter the clinic this year - LEXINGTON, Mass., Nov. 30, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ:  AGEN ), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in a Phase

LEXINGTON, Mass., Nov. 14, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ:  AGEN ), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators and cancer vaccines, today announced that the Company will present at the Jefferies 2016 London

Company to host conference call at 11:00 a.m. ET today LEXINGTON, Mass. , Oct. 27, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators and cancer vaccines, today provided an update

LEXINGTON, Mass., Oct. 20, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ:  AGEN ) will release its third quarter 2016 financial results before the market opens on Thursday, October 27, 2016. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.

LEXINGTON, Mass., Oct. 18, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ:  AGEN ), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators and cancer vaccines, today announced the appointment of James Gorman, M.D., Ph.D.

LEXINGTON, Mass., Sept. 6, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ:  AGEN ), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the Company will present at the Rodman & Renshaw 18th

Company to host conference call at 11:00 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN) will release its second quarter 2016 financial results before the market opens on Thursday, July 28, 2016. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced the appointment of Jean-Marie Cuillerot, M.D.

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Robert B. Stein, M.D., Ph.D., President, Research & Development, will present

Received First Milestone Payment of $2 Million LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines, today announced the selection of a lead

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00